Company intelligence / Profile preview

Psylin Neurosciences

Tarrytown, New York, United States

Ownership: Private
Development stage: Other

Overview

Psylin Neurosciences was a biotechnology joint venture established in 2007 by PsychoGenics and Link Medicine to discover and develop small molecule therapies for central nervous system disorders. The company primarily focused on treatment-resistant depression and anxiety, utilizing PsychoGenics' proprietary SmartCube phenotypic screening platform. Its lead research efforts targeted GPR3, an orphan G-protein coupled receptor believed to play a role in mood regulation. The venture effectively ceased operations as an independent entity following the acquisition of Link Medicine by AstraZeneca in 2012.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

PsychoGenicsLink Medicine

Beyond the preview

Go deeper on Psylin Neurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psylin Neurosciences.

Explore the full profile